Glioblastoma

The FDA granted orphan drug designation to several therapies in development for oncology indications.

CHICAGO — The addition of veliparib to adjuvant temozolomide did not extend OS or PFS among patients with newly diagnosed MGMT hypermethylated glioblastoma, according to results of a randomized phase 2/phase 3 trial presented at ASCO Annual Meeting.

May is Brain Cancer Awareness Month.

Break Through Cancer will award $50 million in grants designed to maximize interdisciplinary collaboration among researchers at five top cancer centers.

SEATTLE — Although advancements have been made in immune checkpoint inhibitors, tumors such as glioblastoma present a roadblock to successful therapy, according to a presenter at the 2022 American Academy of Neurology annual meeting.

Yes: Brachytherapy for the treatment of intracranial malignancies holds tremendous promise for optimal management of these frequently complex patients.

Although therapeutic advances during the past decade have dramatically improved cancer outcomes overall, the outlook for patients with malignant brain tumors has remained poor.

Surgeons at Lenox Hill Hospital are recruiting patients for a first-in-human, single arm, open-label phase 1 clinical trial investigating the safety and feasibility of using belly fat to treat recurrent glioblastoma.

A personalized cancer vaccine conferred a PFS benefit to a subset of patients with newly diagnosed glioblastoma, according to phase 2 study results presented at Society for the Immunotherapy of Cancer Annual Meeting.

John F. de Groot, MD, has been appointed chief of the neuro-oncology division at University of California, San Francisco.